GSK reveals encouraging Seretide test results

GlaxoSmithKline (GSK) has announced the preliminary results for its latest Seretide trial for patients with obstructive pulmonary disease (COPD).

The Towards a Revolution in COPD Health (Torch) study showed a reduction of 17 per cent in the mortality rate of people being treated with the drug, compared to those who received a placebo.

Furthermore, those taking Seretide also saw a decrease of 25 per cent in COPD exacerbations, compared to the placebo group.

The drug manufacturer, GSK, believes that the results of the trial are “clinically important” and that it will have a “positive impact” on the management of COPD.

GSK will now look to publish the results of the study in a peer-reviewed journal as soon as possible.

© Adfero Ltd